Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

2.1. Antibodies and Plasma

MG Mandy Gruijs
RB Rens Braster
MO Marije B. Overdijk
TH Tessa Hellingman
SV Sandra Verploegen
RK Rianne Korthouwer
BW Berend J. van der Wilk
PP Paul W. H. I. Parren
HV Hans J. van der Vliet
MB Marijn Bögels
ME Marjolein van Egmond
request Request a Protocol
ask Ask a question
Favorite

The therapeutic anti-EGFR mAbs cetuximab and panitumumab were purchased from Merck (Schiphol-Rijk, the Netherlands) and Amgen (Breda, the Netherlands), respectively. Zalutumumab (HuMax-EGFR, clone 2F8) was generated by Genmab (Utrecht, the Netherlands) as described previously [36].

Plasma from 10 metastatic KRAS wild-type colorectal cancer patients (mean age: 60.6 years (50–73 years), 6 males) previously treated with and progressive after systemic palliative chemotherapy was obtained before and four hours after an initial dose of cetuximab (500 mg/m2 i.v.), administered as part of the COLOCETUX trial (NCT01691391) [37]. The trial was approved by the medical ethical committee of the Amsterdam UMC, location VUmc. All patients signed informed consent according to Dutch and international law.

Copyright and License information:  ©2022 Mandy Gruijs et al.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A